EcoDrugPlus

Egl-9 Family Hypoxia-Inducible Factor 2

Ensembl ID : ENSOMYG00000022630
Gene Symbol: EGLN2
1 Cross references
185 Possible Orthologues:

Egl-9 Family Hypoxia-Inducible Factor 3

Ensembl ID : ENSOMYG00000038907
Gene Symbol: EGLN3
1 Cross references
147 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSOMYG00000028097
Gene Symbol: EPAS1
1 Cross references
205 Possible Orthologues:

Endothelial Pas Domain Protein 1

Ensembl ID : ENSOMYG00000034554
Gene Symbol: EPAS1
1 Cross references
205 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSOMYG00000032607
Gene Symbol: ECE1
1 Cross references
223 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSOMYG00000031040
Gene Symbol: ECE1
1 Cross references
223 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSOMYG00000049903
Gene Symbol: EDNRA
1 Cross references
197 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSOMYG00000011872
Gene Symbol: EDNRAA
1 Cross references
201 Possible Orthologues:

Endothelin Receptor Type Aa

Ensembl ID : ENSOMYG00000011025
Gene Symbol: EDNRAA
1 Cross references
197 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSOMYG00000008028
Gene Symbol: EZH2
1 Cross references
235 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSOMYG00000044543
Gene Symbol: EGFRA
1 Cross references
206 Possible Orthologues:

Epidermal Growth Factor Receptor A (Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog, Avian)

Ensembl ID : ENSOMYG00000030173
Gene Symbol: EGFRA
1 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).